Progress report on new antiepileptic drugs: A summary of the Sixteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVI): II. Drugs in more advanced clinical development.

Autor: Bialer M; Institute for Drug Research, Faculty of Medicine, School of Pharmacy, and David R. Bloom Center for Pharmacy, Hebrew University of Jerusalem, Jerusalem, Israel., Johannessen SI; National Center for Epilepsy, Sandvika, Norway.; Department of Pharmacology, Oslo University Hospital, Oslo, Norway., Koepp MJ; Department of Clinical and Experimental Epilepsy, University College London Queen Square Institute of Neurology, London, UK., Levy RH; Department of Pharmaceutics and Neurological Surgery, University of Washington, Seattle, Washington, USA., Perucca E; Department of Medicine (Austin Health), University of Melbourne, Melbourne, Victoria, Australia.; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia., Perucca P; Department of Medicine (Austin Health), University of Melbourne, Melbourne, Victoria, Australia.; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia.; Bladin-Berkovic Comprehensive Epilepsy Program, Department of Neurology, Austin Health, Melbourne, Victoria, Australia.; Department of Neurology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.; Department of Neurology, Alfred Health, Melbourne, Victoria, Australia., Tomson T; Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden., White HS; Department of Pharmacy, School of Pharmacy, University of Washington, Seattle, Washington, USA.
Jazyk: angličtina
Zdroj: Epilepsia [Epilepsia] 2022 Nov; Vol. 63 (11), pp. 2883-2910. Date of Electronic Publication: 2022 Aug 11.
DOI: 10.1111/epi.17376
Abstrakt: The Sixteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVI) was held in Madrid, Spain on May 22-25, 2022 and was attended by 157 delegates from 26 countries representing basic and clinical science, regulatory agencies, and pharmaceutical industries. One day of the conference was dedicated to sessions presenting and discussing investigational compounds under development for the treatment of seizures and epilepsy. The current progress report summarizes recent findings and current knowledge for seven of these compounds in more advanced clinical development for which either novel preclinical or patient data are available. These compounds include bumetanide and its derivatives, darigabat, ganaxolone, lorcaserin, soticlestat, STK-001, and XEN1101. Of these, ganaxolone was approved by the US Food and Drug Administration in March 2022 for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder in patients 2 years of age and older.
(© 2022 International League Against Epilepsy.)
Databáze: MEDLINE
Externí odkaz: